Table of Contents
Display 4-1: Therapies that Disqualified Patients as Responders
Display 4-14: Proportions of Patients Responding in Courses 1 and 2 of Study 711
Display 4-15: Study 711 – Proportion of Patients Achieving PASI 75 by Course
Immunizations Coincided With Maximal CD4+ Memory T-Cell Reduction
Percentage of Patients With Anti-?X174 IgG ?30% of Total Anti-?X174 Response*
Squamous Cell Carcinoma of Skin by Course of Alefacept
Incidence of Injection Site Reactions
Injection Site Reactions by Severity
Malignancy Rates: Invasive Squamous Cell Cancers
PASI 75 at 2 Weeks After Last Dose by Quartiles of Weight
Baseline Characteristics of Patients Who Developed SCC or BCC
Mean EAUC CD4+ Memory by Weight Quartile
Efficacy Summary: IV vs IM
DTH Response Converting from Positive to Negative
DTH Response Converting from Positive to Negative
Influence of Concomitant Medications on the Primary Endpoint
PPT Slide
Estimated Incidence of Serious Adverse Events
Changes in Lesional Skin: Histologic Responders vs Nonresponders
Effect of Alefacept on Circulating CD4+ T-Cell Subsets*
Incidence of B Cell Lymphoma in Nonhuman Primates
|